Dataset Information


Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.

ABSTRACT: BACKGROUND:Ileocolonic expression of IL13RA2 has been identified as a predictive marker for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD). AIM:To validate the IL13RA2 biomarker, study its anti-TNF specificity and get a better understanding of the underlying biology driving its expression. METHODS:IL13RA2 mucosal expression was studied in a cohort of adalimumab and vedolizumab treated patients. To identify the upstream regulators of anti-TNF nonresponsiveness, weighted gene co-expression network analysis was applied on publicly available microarray data of IFX-treated patients. Selected serum proteins, including TNF, were measured prior to first IFX exposure and compared between healers and nonhealers. RESULTS:Increased mucosal IL13RA2 expression prior to start of biological therapy was predictive for anti-TNF nonresponsiveness specifically (AUROC, area under the curve = 0.90, P < 0.001 in anti-TNF vs AUROC = 0.63, P = 0.30 in vedolizumab treated patients). In baseline biopsies, TNF-driven pathways were significantly enriched in future anti-TNF nonhealers (P = 5.0 × 10-34 ). We found an increased baseline mucosal TNF burden in nonhealers (P = 0.02), and TNF mRNA correlated significantly with IL13RA2 expression (? = 0.55, P = 0.02). Baseline serum TNF levels were significantly lower in nonhealers (P = 0.04), and correlated inversely with IFX serum induction levels (r = -0.45, P = 0.002 at week 6). CONCLUSIONS:Increased mucosal IL13RA2 expression is associated with an increased mucosal TNF burden in CD patients. In view of its specificity for prediction of anti-TNF therapy resistance, mucosal IL13RA2 expression is a potential biomarker for therapy selection and/or for the need of increased anti-TNF drug dosing.

SUBMITTER: Verstockt B 

PROVIDER: S-EPMC6849553 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6305625 | BioStudies
2020-01-01 | S-EPMC7143962 | BioStudies
2016-10-11 | GSE73661 | GEO
2019-01-01 | S-EPMC6413341 | BioStudies
2018-01-01 | S-EPMC6289430 | BioStudies
2016-01-01 | S-EPMC5077077 | BioStudies
1000-01-01 | S-EPMC4917292 | BioStudies
2010-01-01 | S-EPMC2911911 | BioStudies
2017-01-01 | S-EPMC5218976 | BioStudies
1000-01-01 | S-EPMC5886978 | BioStudies